| pubmed-article:8207119 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8207119 | lifeskim:mentions | umls-concept:C0030481 | lld:lifeskim |
| pubmed-article:8207119 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8207119 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:8207119 | lifeskim:mentions | umls-concept:C0077503 | lld:lifeskim |
| pubmed-article:8207119 | lifeskim:mentions | umls-concept:C1749467 | lld:lifeskim |
| pubmed-article:8207119 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:8207119 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:8207119 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8207119 | pubmed:dateCreated | 1994-7-12 | lld:pubmed |
| pubmed-article:8207119 | pubmed:abstractText | Tumor necrosis factor-alpha (TNF-alpha) is a potent mediator produced by activated T lymphocytes and macrophages, which may play a role in the pathogenesis and development of multiple sclerosis (MS) and HTLV-1-associated myelopathy (HAM). The first step in the induction of many biological effects elicited by TNF-alpha is its binding to specific cell surface receptors. A soluble form of TNF receptor (sTNF-R) can be detected in the body fluid. We measured sTNF-R levels in the sera and cerebrospinal fluid (CSF) of patients with either MS or HAM, and evaluated the correlation between this mediator and disease activity. The levels of sTNF-R in the sera and CSF of patients with MS were significantly increased compared with controls, particularly patients with acute relapsing MS during an exacerbation (P < 0.001). CSF levels of sTNF-R showed a strong correlation with those of TNF (r = 0.716, P < 0.001). Higher levels of sTNF-R in the sera of HAM patients were detected as compared with those of either controls (P < 0.001) or non-HAM carriers (P < 0.001). Patients with HAM exhibited significantly higher CSF levels of sTNF-R than those with other neurological diseases (P < 0.0001). These results suggest that the detection of sTNF-R in the sera and CSF may predict disease progression. Availability of such a marker would be useful in monitoring disease activity. | lld:pubmed |
| pubmed-article:8207119 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8207119 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8207119 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8207119 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8207119 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8207119 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8207119 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8207119 | pubmed:issn | 0165-5728 | lld:pubmed |
| pubmed-article:8207119 | pubmed:author | pubmed-author:MatsudaMM | lld:pubmed |
| pubmed-article:8207119 | pubmed:author | pubmed-author:YanagisawaNN | lld:pubmed |
| pubmed-article:8207119 | pubmed:author | pubmed-author:MiyagiKK | lld:pubmed |
| pubmed-article:8207119 | pubmed:author | pubmed-author:TsukadaNN | lld:pubmed |
| pubmed-article:8207119 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8207119 | pubmed:volume | 52 | lld:pubmed |
| pubmed-article:8207119 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8207119 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8207119 | pubmed:pagination | 33-40 | lld:pubmed |
| pubmed-article:8207119 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:meshHeading | pubmed-meshheading:8207119-... | lld:pubmed |
| pubmed-article:8207119 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8207119 | pubmed:articleTitle | Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-1-associated myelopathy. | lld:pubmed |
| pubmed-article:8207119 | pubmed:affiliation | Department of Medicine (Neurology), Shinshu University, School of Medicine, Matsumoto, Japan. | lld:pubmed |
| pubmed-article:8207119 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8207119 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8207119 | lld:pubmed |
